Reference data : LOINC code

Filter


Clear filter

Results
104,672 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType DefinitionDescription dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
102013-0 Have you tried not to think about or avoided situations that reminded you of the event(s) Find ^Patient 1Mo Ord PC-PTSD-5   ACTIVE Have you tried not to think about or avoided situations that reminded you of the event(s) [PC-PTSD-5]   NAM DefinitionDescription                   SURVEY.MTLHLTH   102013-0   PC-PTSD-5     Observation       0       Have you tried not to think about or avoided situations that reminded you of the event(s)? N   1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; S prime; Screen; Survey; SURVEY.MTLHLTH 2.77 2.75                       0
102014-8 Have you been constantly on guard, watchful, or easily startled Find ^Patient 1Mo Ord PC-PTSD-5   ACTIVE Have you been constantly on guard, watchful, or easily startled [PC-PTSD-5]   NAM DefinitionDescription                   SURVEY.MTLHLTH   102014-8   PC-PTSD-5     Observation       0       Have you been constantly on guard, watchful, or easily startled? N   1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH 2.77 2.75                       0
102015-5 Have you felt numb or detached from people, activities, or your surroundings Find ^Patient 1Mo Ord PC-PTSD-5   ACTIVE Have you felt numb or detached from people, activities, or your surroundings [PC-PTSD-5]   NAM DefinitionDescription                   SURVEY.MTLHLTH   102015-5   PC-PTSD-5     Observation       0       Have you felt numb or detached from people, activities, or your surroundings? N   1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH 2.77 2.75                       0
102016-3 Have you felt guilty or unable to stop blaming yourself or others for the event(s) or any problems the event(s) may have caused Find ^Patient 1Mo Ord PC-PTSD-5   ACTIVE Have you felt guilty or unable to stop blaming yourself or others for the event(s) or any problems the event(s) may have caused [PC-PTSD-5]   NAM DefinitionDescription                   SURVEY.MTLHLTH   102016-3   PC-PTSD-5     Observation       0       Have you felt guilty or unable to stop blaming yourself or others for the event(s) or any problems the event(s) may have caused? N   1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; S prime; Screen; Survey; SURVEY.MTLHLTH 2.77 2.75                       0
102017-1 PC-PTSD-5 score Score ^Patient 1Mo Qn PC-PTSD-5   ACTIVE PC-PTSD-5 score [PC-PTSD-5]   ADD DefinitionDescription     score             SURVEY.MTLHLTH   102017-1   PC-PTSD-5     Observation       0         N   1 month; 1 month (30 days); 30 days; QNT; Quan; Quant; Quantitative; Scale; Survey; SURVEY.MTLHLTH 2.75 2.75               {score}       0
102018-9 Glucose^1H post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Glucose [Mass/volume] in Serum or Plasma --1 hour post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102018-9         Both       0 Glucose 1h p Gc SerPl-mCnc       N   1 hour; 1.0Hr; 1h p Gc; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HGF; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mmol/L       0
102019-7 Glucose^1.5H post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102019-7         Both       0 Glucose 1.5h p Gc SerPl-mCnc       N   1 1/2 hours; 1 1/2 HR; 1.5h p Gc; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HGF; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mg/dL       0
10202-0 Physical findings Find Neurologic system Pt Nar Observed   ACTIVE Physical findings of Nervous system Narrative   MIN DefinitionDescription                   H&P.PX   10202-0   Observed             0 Phys find Neurologic           Exam; Examination; Finding; Findings; H+P; H+P.PX; Narrative; P prime; Phys find; Point in time; Random; Report 2.4 1.0i                       0
102020-5 Glucose^2H post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Glucose [Mass/volume] in Serum or Plasma --2 hours post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102020-5         Both       0 Glucose 2h p Gc SerPl-mCnc       N   120 min; 120 minutes; 120min; 2 hours; 2h p Gc; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HGF; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mmol/L       0
102021-3 Glucose^2.5H post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Glucose [Mass/volume] in Serum or Plasma --2.5 hours post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102021-3         Both       0 Glucose 2.5h p Gc SerPl-mCnc       N   2.5h p Gc; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HGF; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mmol/L       0
102022-1 Glucose^3H post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Glucose [Mass/volume] in Serum or Plasma --3 hours post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102022-1         Both       0 Glucose 3h p Gc SerPl-mCnc       N   3h p Gc; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HGF; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mmol/L       0
102023-9 Cortisol^30M post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Cortisol [[Mass/volume] in Serum or Plasma --30 minutes post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102023-9         Both       0 Cortis 30M p Gc SerPl-mCnc       N   17-Hydroxycorticosterone; 30M p Gc; After; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; HGF; hydrocortisone; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mg/dL       0
102024-7 Cortisol^60M post dose glucagon SCnc Ser/Plas Pt Qn     ACTIVE Cortisol [Moles/volume] in Serum or Plasma --60M post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102024-7         Both       0 Cortis 60M post dose glucagon SerPl-sCnc       N   17-Hydroxycorticosterone; After; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; HGF; hydrocortisone; Hyperglycemic factor; Level; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration 2.75 2.75               mg/dL       0
102025-4 Cortisol^1.5H post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Cortisol [Mass/volume] in Serum or Plasma --1.5 hours post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102025-4         Both       0 Cortis 1.5h p Gc SerPl-mCnc       N   1 1/2 hours; 1 1/2 HR; 1.5h p Gc; 1.5Hr; 17-Hydroxycorticosterone; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; HGF; hydrocortisone; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mg/dL       0
102026-2 Cortisol^2H post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Cortisol [Mass/volume] in Serum or Plasma --2 hours post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102026-2         Both       0 Cortis 2h p Gc SerPl-mCnc       N   120 min; 120 minutes; 120min; 17-Hydroxycorticosterone; 2 hours; 2h p Gc; After; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; HGF; hydrocortisone; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mg/dL       0
102027-0 Cortisol^2.5H post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Cortisol [Mass/volume] in Serum or Plasma --2.5 hours post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102027-0         Both       0 Cortis 2.5h p Gc SerPl-mCnc       N   17-Hydroxycorticosterone; 2.5h p Gc; After; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; HGF; hydrocortisone; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mg/dL       0
102028-8 Cortisol^3H post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Cortisol [Mass/volume] in Serum or Plasma --3 hours post dose glucagon   ADD DefinitionDescription     mg/dL             CHAL   102028-8         Both       0 Cortis 3h p Gc SerPl-mCnc       N   17-Hydroxycorticosterone; 3h p Gc; After; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; HGF; hydrocortisone; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.75 2.75               mg/dL       0
102029-6 Somatotropin^Fasting post dose insulin IV MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --Fasting post dose insulin IV   ADD DefinitionDescription     mg/dL             CHAL   102029-6         Both       0 GH^ post insulin IV post CFst SerPl-mCnc       N   After; CHEMISTRY.CHALLENGE TESTING; Fast p insulin IV; GH; Growth hormone; HGH; HUM; Human growth hormone; Humulin; IH7; Insul; Lente; Level; Mass concentration; NPH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatotropic hormone; SR; STH; Ultralente 2.75 2.75               mg/dL       0
10203-8 Physical findings Find Nose Pt Nar Observed   ACTIVE Physical findings of Nose Narrative   MIN DefinitionDescription                   H&P.PX   10203-8   Observed             0 Phys find Nose           Exam; Examination; Finding; Findings; H+P; H+P.PX; Narrative; Nasal; Nos; Nose (nasal passage); P prime; Phys find; Point in time; Random; Report; Smell 2.4 1.0i                       0
102030-4 Ki-67 Nuclear Ag & p16INK4a Ag PrThr Body fld Pt Ord Immune stain   ACTIVE Ki-67 Nuclear Ag and p16INK4a Ag Ag [Presence] in Body fluid by Immune stain   MIN DefinitionDescription           N/A       CELLMARK   102030-4   Immune stain     Both       0 Ki-67 Nuc Ag & p16INK4a Ag Fld Ql       N   Antigen; Antigens; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; CELL MARKERS; Fl; Fld; FLU; Fluid; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ki/SL; KI-67; Ki-67 Nuc Ag p16INK4a Ag; Ki-67 nuc Ag+ p16INK4a Ag; Ki-67 Nuclear Ag p16INK4a Ag; Mindbomb homolog 1; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SL; SL-Ki; St; Stains; Stn 2.77 2.75                     Release 2.77: LONG_COMMON_NAME: removed double space; 0
102031-2 Ki-67 Nuclear Ag & p16INK4a Ag PrThr Cvx Pt Ord Immune stain   ACTIVE Ki-67 Nuclear Ag and p16INK4a Ag Ag [Presence] in Cervix by Immune stain   ADD DefinitionDescription           N/A       CELLMARK   102031-2   Immune stain     Both       0 Ki-67 Nuc Ag & p16INK4a Ag Ag Cvx Ql       N   Antigen; Antigens; CELL MARKERS; Cervix; Genital tract; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ki/SL; KI-67; Ki-67 Nuc Ag p16INK4a Ag; Ki-67 nuc Ag+ p16INK4a Ag; Ki-67 Nuclear Ag p16INK4a Ag; Mindbomb homolog 1; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SL; SL-Ki; St; Stains; Stn 2.75 2.75                       0
102032-0 Glucose^2H post dose insulin IV MCnc Ser/Plas Pt Qn     ACTIVE Glucose [Mass/volume] in Serum or Plasma --2 hours post dose insulin IV   ADD DefinitionDescription     mg/dL             CHAL   102032-0         Both       0 Glucose 2h p Ins IV SerPl-mCnc       N   120 min; 120 minutes; 120min; 2 hours; 2h p Ins IV; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HUM; Humulin; IH7; Insul; Lente; Level; Mass concentration; NPH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente 2.75 2.75               mg/dL       0
102033-8 Pathology network list Find Personnel Pt Nom     ACTIVE Personnel Pathology network list   MAJ DefinitionDescription                   ADMIN   102033-8                 0 Personnel Pathology network list       N   ADMIN; Finding; Findings; Nominal; Path; Point in time; Random; Specialist 2.76 2.75                       0
102034-6 Path report.microscopic observation Find Specimen Pt Nom     ACTIVE Pathology report microscopic observation in Specimen   ADD DefinitionDescription                   PATH   102034-6         Both       0 Path report.microscopic Spec       N   Finding; Findings; Nominal; Pathology; Point in time; Random; Spec 2.75 2.75                       0
102035-3 Screening anti-hypertensive and anti-thrombotic drugs PrThr Ser Pt Ord LC/MS/MS   ACTIVE Anti-hypertensive and Anti-thrombotic drug [Presence] in Serum by LC/MS/MS   ADD DefinitionDescription                   DRUGDOSE   102035-3   LC/MS/MS     Both       0 HTN and ATT drug LC/MS/MS       N   Asympt; Asymptomatic; Drug; DRUG DOSES; HTN and ATT drug LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Screen; Serum; SR 2.75 2.75                       0
104,672 results found